A Randomized, Placebo-controlled, Double-blind Study to Evaluate Safety and Dose Dependent Clinical Efficacy of APO-2 at Three Different Doses in Patients With Diabetic Foot Ulcer
Latest Information Update: 11 Mar 2024
At a glance
- Drugs Apoptotic blood mononuclear cell therapy (Primary) ; Apoptotic blood mononuclear cell therapy (Primary)
- Indications Diabetic foot ulcer
- Focus First in man; Therapeutic Use
- Acronyms MARSYAS II
- Sponsors Aposcience
Most Recent Events
- 30 Jan 2024 Status changed from active, no longer recruiting to completed.
- 06 Jan 2024 This trial has been completed in Czech Republic (Global end date: 6 Dec 2023).
- 19 Dec 2023 This trial has been completed in Germany, according to European Clinical Trials Database record.